Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?

Table 2 Comorbidities by ART exposure: prevalence and adjusted rate ratios (aRR) for morbidity risk (reference category ≤ 3 years)

Comorbidity	Total		ART exposure					> 3 vs ≤ 3 years
	Total		≤ 3 years		> 3 years		P	aRR	95% CI
	N	%	N	%	N	%	P
	1394	100	323	23.2	1071	76.8
Dyslipidemia	909	65.2	169	52.3	740	69.1	< 0.0001	1.35	1.20–1.52
Hypertension	440	31.6	73	22.6	367	34.3	< 0.0001	1.52	1.22–1.89
Hypovitaminosis D	342	24.5	46	14.2	296	17.6	< 0.0001	1.86	1.40–2.49
Liver disease	285	20.4	42	13.0	243	22.7	0.0002	1.78	1.32–2.41
CNS disturbance	201	14.4	52	16.1	149	13.9	0.33	0.78	0.56–1.05
Renal impairment	152	10.9	28	8.7	124	11.6	0.14	1.39	0.92–2.09
Osteopenia/osteoporosis	148	10.6	13	4.0	135	12.6	< 0.0001	2.88	1.65–5.03
Diabetes	124	8.9	29	9.0	95	8.9	0.95	1.06	0.70–1.60
Other CVD	114	8.2	19	5.9	95	8.9	0.09	1.40	0.87–2.26
Obesity	110	7.8	19	5.9	91	8.5	0.13	1.48	0.91–2.40
Epilepsy	57	4.1	6	1.9	51	4.8	0.02	2.06	0.88–4.82
Non-AIDS-related malignancies	49	3.5	9	2.8	40	3.7	0.42	1.25	0.61–2.59
Lung disease	37	2.6	9	2.8	28	2.6	0.87	0.91	0.43–1.90
Multimorbidity	852	61.1	153	47.4	699	65.3	< 0.0001	1.36	1.21–1.54

ART antiretroviral treatment, CI confidence interval, CNS central nervous system, CVD cardiovascular disease, aRR adjusted rate ratio

ISSN: 1471-2334